Integra LifeSciences Holdings (IART) Stock Overview
Manufactures and sells surgical instrument, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
IART Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Integra LifeSciences Holdings Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.12 |
| 52 Week High | US$27.13 |
| 52 Week Low | US$11.06 |
| Beta | 1.17 |
| 1 Month Change | 15.64% |
| 3 Month Change | 8.53% |
| 1 Year Change | -33.71% |
| 3 Year Change | -74.27% |
| 5 Year Change | -71.37% |
| Change since IPO | 205.30% |
Recent News & Updates
Recent updates
Is Integra LifeSciences Holdings (NASDAQ:IART) Using Too Much Debt?
Jul 21
Integra LifeSciences Holdings Corporation's (NASDAQ:IART) 28% Dip In Price Shows Sentiment Is Matching Revenues
May 11Integra LifeSciences Holdings Corporation (NASDAQ:IART) Looks Inexpensive But Perhaps Not Attractive Enough
Mar 27Integra LifeSciences: Light At The End Of The Tunnel, Or Another Oncoming Train? (Rating Upgrade)
Mar 06These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Extensively
Jan 31There's No Escaping Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Muted Revenues Despite A 42% Share Price Rise
Nov 05Is Now The Time To Look At Buying Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Oct 24
LifeSciences' Strategic Moves To Boost Quality And Compliance For Long-term Profit Growth
Investing in compliance and quality improvements aims to enhance product supply reliability and support long-term revenue growth by meeting market demand.Why Investors Shouldn't Be Surprised By Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Low P/S
Sep 08Is Integra LifeSciences Holdings (NASDAQ:IART) A Risky Investment?
Aug 21At US$29.14, Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Worth Looking At Closely?
Jul 01Integra LifeSciences Still Underperforming As Manufacturing Issues Linger
Jun 21Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Intrinsic Value Is Potentially 40% Above Its Share Price
May 28Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Stalled
Feb 27We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt
Feb 11Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Jan 14Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Price In Tune With Earnings
Dec 31Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 46% Discount?
Dec 03Does Integra LifeSciences Holdings (NASDAQ:IART) Have A Healthy Balance Sheet?
Nov 06Integra LifeSciences Holdings (NASDAQ:IART) Hasn't Managed To Accelerate Its Returns
Oct 24Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Sep 22Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 38% Discount?
Aug 15Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Hit The Brakes
Jul 03Is There Now An Opportunity In Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Jun 19Estimating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)
May 05These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well
Apr 07Integra LifeSciences Holdings (NASDAQ:IART) Is Experiencing Growth In Returns On Capital
Mar 26At US$52.61, Is It Time To Put Integra LifeSciences Holdings Corporation (NASDAQ:IART) On Your Watch List?
Mar 14Shareholder Returns
| IART | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 14.1% | 2.7% | 1.9% |
| 1Y | -33.7% | 7.9% | 19.4% |
Return vs Industry: IART underperformed the US Medical Equipment industry which returned 7.8% over the past year.
Return vs Market: IART underperformed the US Market which returned 19.6% over the past year.
Price Volatility
| IART volatility | |
|---|---|
| IART Average Weekly Movement | 8.0% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: IART has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: IART's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 4,396 | Mojdeh Poul | www.integralife.com |
Integra LifeSciences Holdings Corporation manufactures and sells surgical instrument, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
Integra LifeSciences Holdings Corporation Fundamentals Summary
| IART fundamental statistics | |
|---|---|
| Market cap | US$1.07b |
| Earnings (TTM) | -US$500.63m |
| Revenue (TTM) | US$1.62b |
Is IART overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IART income statement (TTM) | |
|---|---|
| Revenue | US$1.62b |
| Cost of Revenue | US$688.92m |
| Gross Profit | US$932.82m |
| Other Expenses | US$1.43b |
| Earnings | -US$500.63m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.43 |
| Gross Margin | 57.52% |
| Net Profit Margin | -30.87% |
| Debt/Equity Ratio | 177.4% |
How did IART perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/13 03:36 |
| End of Day Share Price | 2025/08/13 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Integra LifeSciences Holdings Corporation is covered by 31 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Matthew Taylor | Barclays |
| Charley Jones | Barrington Research Associates, Inc. |